FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1756552807> ?p ?o ?g. }

• W1756552807 endingPage "151" @default.
• W1756552807 startingPage "151" @default.
• W1756552807 abstract "Hyperkalemia is a potentially life-threatening condition predominantly seen in patients treated with renin-angiotensin-aldosterone system (RAAS) inhibitors with stage 3 or greater chronic kidney disease (CKD) who may also have diabetes, heart failure, or both.To select starting doses for a phase 3 study and to evaluate the long-term safety and efficacy of a potassium-binding polymer, patiromer, in outpatients with hyperkalemia.Phase 2, multicenter, open-label, dose-ranging, randomized clinical trial (AMETHYST-DN), conducted at 48 sites in Europe from June 2011 to June 2013 evaluating patiromer in 306 outpatients with type 2 diabetes (estimated glomerular filtration rate, 15 to <60 mL/min/1.73 m2 and serum potassium level >5.0 mEq/L). All patients received RAAS inhibitors prior to and during study treatment.Patients were stratified by baseline serum potassium level into mild or moderate hyperkalemia groups and received 1 of 3 randomized starting doses of patiromer (4.2 g [n = 74], 8.4 g [n = 74], or 12.6 g [n = 74] twice daily [mild hyperkalemia] or 8.4 g [n = 26], 12.6 g [n = 28], or 16.8 g [n = 30] twice daily [moderate hyperkalemia]). Patiromer was titrated to achieve and maintain serum potassium level 5.0 mEq/L or lower.The primary efficacy end point was mean change in serum potassium level from baseline to week 4 or prior to initiation of dose titration. The primary safety end point was adverse events through 52 weeks. Secondary efficacy end points included mean change in serum potassium level through 52 weeks.A total of 306 patients were randomized. The least squares mean reduction from baseline in serum potassium level at week 4 or time of first dose titration in patients with mild hyperkalemia was 0.35 (95% CI, 0.22-0.48) mEq/L for the 4.2 g twice daily starting-dose group, 0.51 (95% CI, 0.38-0.64) mEq/L for the 8.4 g twice daily starting-dose group, and 0.55 (95% CI, 0.42-0.68) mEq/L for the 12.6 g twice daily starting-dose group. In those with moderate hyperkalemia, the reduction was 0.87 (95% CI, 0.60-1.14) mEq/L for the 8.4 g twice daily starting-dose group, 0.97 (95% CI, 0.70-1.23) mEq/L for the 12.6 g twice daily starting-dose group, and 0.92 (95% CI, 0.67-1.17) mEq/L for the 16.8 g twice daily starting-dose group (P < .001 for all changes vs baseline by hyperkalemia starting-dose groups within strata). From week 4 through week 52, statistically significant mean decreases in serum potassium levels were observed at each monthly point in patients with mild and moderate hyperkalemia. Over the 52 weeks, hypomagnesemia (7.2%) was the most common treatment-related adverse event, mild to moderate constipation (6.3%) was the most common gastrointestinal adverse event, and hypokalemia (<3.5 mEq/L) occurred in 5.6% of patients.Among patients with hyperkalemia and diabetic kidney disease, patiromer starting doses of 4.2 to 16.8 g twice daily resulted in statistically significant decreases in serum potassium level after 4 weeks of treatment, lasting through 52 weeks.clinicaltrials.gov Identifier:NCT01371747." @default.
• W1756552807 created "2016-06-24" @default.
• W1756552807 creator A5008833510 @default.
• W1756552807 creator A5010530190 @default.
• W1756552807 creator A5012514694 @default.
• W1756552807 creator A5033996338 @default.
• W1756552807 creator A5039558708 @default.
• W1756552807 creator A5042843111 @default.
• W1756552807 creator A5056005655 @default.
• W1756552807 creator A5070514003 @default.
• W1756552807 creator A5086409547 @default.
• W1756552807 creator A5091483213 @default.
• W1756552807 date "2015-07-14" @default.
• W1756552807 modified "2023-10-11" @default.
• W1756552807 title "Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease" @default.
• W1756552807 cites W156137423 @default.
• W1756552807 cites W1581048864 @default.
• W1756552807 cites W1967049327 @default.
• W1756552807 cites W1968233365 @default.
• W1756552807 cites W1970537005 @default.
• W1756552807 cites W1970939567 @default.
• W1756552807 cites W1975828955 @default.
• W1756552807 cites W1984363044 @default.
• W1756552807 cites W2015371105 @default.
• W1756552807 cites W2023939263 @default.
• W1756552807 cites W2030933332 @default.
• W1756552807 cites W2041164566 @default.
• W1756552807 cites W2042689611 @default.
• W1756552807 cites W2056976690 @default.
• W1756552807 cites W2059158127 @default.
• W1756552807 cites W2060199433 @default.
• W1756552807 cites W2076612610 @default.
• W1756552807 cites W2093767567 @default.
• W1756552807 cites W2093953712 @default.
• W1756552807 cites W2094727696 @default.
• W1756552807 cites W2095682936 @default.
• W1756552807 cites W2101879409 @default.
• W1756552807 cites W2111876001 @default.
• W1756552807 cites W2119340816 @default.
• W1756552807 cites W2142892047 @default.
• W1756552807 cites W2148910374 @default.
• W1756552807 cites W2149305062 @default.
• W1756552807 cites W2152271789 @default.
• W1756552807 cites W2155965977 @default.
• W1756552807 cites W2172193326 @default.
• W1756552807 cites W2176202833 @default.
• W1756552807 cites W2297164013 @default.
• W1756552807 cites W2324948948 @default.
• W1756552807 cites W2467227824 @default.
• W1756552807 cites W2339793680 @default.
• W1756552807 doi "https://doi.org/10.1001/jama.2015.7446" @default.
• W1756552807 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26172895" @default.
• W1756552807 hasPublicationYear "2015" @default.
• W1756552807 type Work @default.
• W1756552807 sameAs 1756552807 @default.
• W1756552807 citedByCount "342" @default.
• W1756552807 countsByYear W17565528072015 @default.
• W1756552807 countsByYear W17565528072016 @default.
• W1756552807 countsByYear W17565528072017 @default.
• W1756552807 countsByYear W17565528072018 @default.
• W1756552807 countsByYear W17565528072019 @default.
• W1756552807 countsByYear W17565528072020 @default.
• W1756552807 countsByYear W17565528072021 @default.
• W1756552807 countsByYear W17565528072022 @default.
• W1756552807 countsByYear W17565528072023 @default.
• W1756552807 crossrefType "journal-article" @default.
• W1756552807 hasAuthorship W1756552807A5008833510 @default.
• W1756552807 hasAuthorship W1756552807A5010530190 @default.
• W1756552807 hasAuthorship W1756552807A5012514694 @default.
• W1756552807 hasAuthorship W1756552807A5033996338 @default.
• W1756552807 hasAuthorship W1756552807A5039558708 @default.
• W1756552807 hasAuthorship W1756552807A5042843111 @default.
• W1756552807 hasAuthorship W1756552807A5056005655 @default.
• W1756552807 hasAuthorship W1756552807A5070514003 @default.
• W1756552807 hasAuthorship W1756552807A5086409547 @default.
• W1756552807 hasAuthorship W1756552807A5091483213 @default.
• W1756552807 hasConcept C126322002 @default.
• W1756552807 hasConcept C126894567 @default.
• W1756552807 hasConcept C134018914 @default.
• W1756552807 hasConcept C159641895 @default.
• W1756552807 hasConcept C168563851 @default.
• W1756552807 hasConcept C178790620 @default.
• W1756552807 hasConcept C185592680 @default.
• W1756552807 hasConcept C203092338 @default.
• W1756552807 hasConcept C2778198053 @default.
• W1756552807 hasConcept C2778525890 @default.
• W1756552807 hasConcept C2778653478 @default.
• W1756552807 hasConcept C2780243291 @default.
• W1756552807 hasConcept C517785266 @default.
• W1756552807 hasConcept C555293320 @default.
• W1756552807 hasConcept C71924100 @default.
• W1756552807 hasConcept C90924648 @default.
• W1756552807 hasConceptScore W1756552807C126322002 @default.
• W1756552807 hasConceptScore W1756552807C126894567 @default.
• W1756552807 hasConceptScore W1756552807C134018914 @default.
• W1756552807 hasConceptScore W1756552807C159641895 @default.
• W1756552807 hasConceptScore W1756552807C168563851 @default.
• W1756552807 hasConceptScore W1756552807C178790620 @default.

• next